Author

Silvio Danese

IBD treatment algorithm driven by AI
IBD treatment algorithm driven by AI

Silvio Danese

RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY
HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY

Silvio Danese  et al.

LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES
LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Silvio Danese  et al.

LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY
LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY

Silvio Danese  et al.

LONG-TERM SAFETY OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS
LONG-TERM SAFETY OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS

Silvio Danese  et al.

SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS
SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS

EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY
HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY

Silvio Danese

LONG-TERM TREATMENT WITH VEDOLIZUMAB SC IN ULCERATIVE COLITIS: INTERIM RESULTS FROM VISIBLE OLE
LONG-TERM TREATMENT WITH VEDOLIZUMAB SC IN ULCERATIVE COLITIS: INTERIM RESULTS FROM VISIBLE OLE

Silvio Danese  et al.

ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: CHRONIC THERAPY DATA FROM THE VIBRATO UMBRELLA STUDY
ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: CHRONIC THERAPY DATA FROM THE VIBRATO UMBRELLA STUDY

Silvio Danese  et al.

ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: DATA FROM THE VIBRATO UMBRELLA STUDY
ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: DATA FROM THE VIBRATO UMBRELLA STUDY

Silvio Danese  et al.

TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL

Silvio Danese  et al.

SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL
SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

Silvio Danese  et al.

NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE
NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE

Silvio Danese  et al.

EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION
EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

Silvio Danese  et al.

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

Silvio Danese  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

Silvio Danese  et al.

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS
DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Silvio Danese  et al.

Item 41 - 60 / 148
1 2
3
4 5 6 7 8